BB Biotech (BBZA) Stock Price & Analysis
BBZA Stock Chart & Stats
- Day’s Range
- EUR 55.40 - EUR 56.50
- 52-Week Range
- EUR 42.95 - EUR 60.80
- Previous Close
- EUR 55.40
- Volume
- 6,472
- Average Volume (3M)
- 5,447
- Market Cap
- EUR 3.03B
- Enterprise Value
- -EUR 433.37M
- Total Cash (Recent Filing)
- EUR 3.30B
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- 2.6
- Beta
- 0.69
- Next Earnings
- Jan 22, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Mar 23, 2026
- Dividend Yield
- 4.35%
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
A debt-free structure and equity that nearly matches assets provide substantial financial resilience. BB Biotech has limited leverage-related obligations, allowing its portfolio strategy to withstand investment swings while preserving flexibility for capital allocation and shareholder distributions.
Strong Profitability Rebound
The sharp TTM improvement demonstrates that the portfolio can generate substantial earnings when underlying biotech holdings perform well. This rebound strengthens near-term capital resources and shows meaningful earnings power, even though the investment model remains cyclical and results can vary.
Positive Cash Generation
Recent operating and free cash flow of 195.9M indicates that BB Biotech is currently converting its investment activity into significant cash resources. Positive cash generation supports ongoing portfolio management, financial resilience, and the capacity to maintain shareholder returns.
Bears Say
High Earnings Volatility
The return to strong profitability has not established a stable earnings base because earlier periods included large losses and abnormal margins. Dependence on portfolio valuation movements makes future income harder to forecast and can produce substantial swings across reporting periods.
Declining Free Cash Flow
Although current cash generation is positive, the meaningful year-over-year decline and prior negative periods indicate that cash conversion is inconsistent across cycles. This variability can complicate distribution planning and reduce confidence that recent cash resources will persist.
Concentrated Portfolio Exposure
A concentrated portfolio can increase the effect of individual holdings and biotech-sector outcomes on company performance. Because BB Biotech relies on research-driven security selection rather than diversified operating revenue, adverse developments in selected investments may have an outsized impact.
BB Biotech News
BBZA FAQ
What was BB Biotech’s price range in the past 12 months?
What is BB Biotech’s market cap?
When is BB Biotech’s upcoming earnings report date?
How were BB Biotech’s earnings last quarter?
Is BB Biotech overvalued?
Does BB Biotech pay dividends?
What is BB Biotech’s EPS estimate?
How many shares outstanding does BB Biotech have?
What happened to BB Biotech’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BB Biotech?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BB Biotech
BB Biotech AG is an investment fund overseen by Bellevue Asset Management AG. This fund allocates capital to publicly traded companies worldwide, with a primary focus on firms pioneering modern biotechnology, specifically in the development of medications and diagnostic tools. The construction of its investment portfolio is guided by a fundamental analysis approach. Established on November 9, 1993, BB Biotech AG is headquartered in Switzerland.
- Sector
- General
- Industry
- Financial - Conglomerates
- CEO
- Daniel Koller
- Employees
- 10
- Website
- www.bbbiotech.ch/ch-en/private
- Address
- Seestrasse 16, Kusnacht, CH-8700, CH
BB Biotech (BBZA) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 5 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 12 | 0 | 0 |